Circulating insulin antibodies during therapy with highly purified neutrally buffered insulins including desphe insulins. Report of a prospective study with 40 cases.
Circulating insulin binding capacity was studied for 10 to 24 months in forty diabetic patients who were being treated with insulin for the first time. They received either neutral highly purified pork insulin, bovine or porcine desphe insulin containing formulations, semisynthetic human insulin, or "conventional" acid chromatographed bovine surfen insulin over the entire duration of the study. In only 6 of the 23 patients on pork insulin, porcine desphe insulin, or human insulin were minimal antibody concentrations (less than or equal to 2 IU/l) observed. The bovine desphe insulin containing beef insulin, was markedly more immunogenic: only 3 out of 12 patients did not produce any antibodies. All five patients treated with bovine surfen insulin reacted with a strong antibody formation, which was, on average, six times as high as that in the patients on bovine desphe insulin (approximately 90 vs 14 IU/l). According to these results, bovine desphe insulins should be considered more valuable in insulin therapy than formulations of unmodified beef or of mixed beef/pork insulins.
D001666:Binding Sites, Antibody; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000276:immunology*; D061389:Insulin, Regular, Pork; D011446:Prospective Studies
D007328:Insulin; D007330:Insulin Antibodies; D061389:Insulin, Regular, Pork; C030808:insulin, (B1)-des-Phe-; C000006:insulin, neutral